Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line

Nuclear Medicine and Biology

Volumn 33, Issue 7, 2006, Pages 875-882

  Jeong, Hwanjeong ^a   Kim, Yu Ri ^b   Kim, Ki Nam ^b   Choe, Jae Gol ^c   Chung, June Key ^d   Kim, Meyoung Kon ^b  

^a Wonkwang University   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Korea University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Gene expression profile; Microarray; Nuclear medicine; Radioiodine therapy; Retinoid acid; Sodium iodide symporter (NIS); Thyroid cancer

Indexed keywords

COTRANSPORTER; DNA; MESSENGER RNA; RADIOACTIVE IODINE; RETINOIC ACID; SODIUM IODIDE SYMPORTER; TRANSFER RNA;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG UPTAKE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; THYROID CARCINOMA; UPREGULATION;

CARCINOMA; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IODINE RADIOISOTOPES; METABOLIC CLEARANCE RATE; NEOPLASM PROTEINS; RADIOPHARMACEUTICALS; SYMPORTERS; THYROID NEOPLASMS; TRETINOIN;

EID: 33749430081     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.07.004     Document Type: Article

References (46)

1. Haugen B.R., Larson L.L., Pugazhenthi U., Hays W.R., Klopper J.P., Kramer C.A., et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89 (2004) 272-280
2. Dentice M., Luongo C., Elefante A., Romino R., Ambrosio R., Vitale M., et al. Transcription factor Nkx-2.5 induces sodium/iodide symporter gene expression and participates in retinoic acid- and lactation-induced transcription in mammary cells. Mol Cell Biol 24 (2004) 7863-7877
3. Lee Y.J., Chung J.K., Shin J.H., Kang J.H., Jeong J.M., Lee D.S., et al. In vitro and in vivo properties of a human anaplastic thyroid carcinoma cell line transfected with the sodium iodide symporter gene. Thyroid 14 (2004) 889-895
4. Dulgeroff A.J., and Hershman J.M. Medical therapy for differentiated thyroid carcinoma. Endocr Rev 15 (1994) 500-515
5. Schmutzler C., Winzer R., Meissner-Weigl J., and Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240 (1997) 832-838
6. Chung J.K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 43 (2002) 1188-1200
7. Shen D.H., Marsee D.K., Schaap J., Yang W., Cho J.Y., Hinkle G., et al. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy. Gene Ther 11 (2004) 161-169
8. Dohan O., and Carrasco N. Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213 (2003) 59-70
9. - symporter-transfected follicular thyroid carcinoma cell line. Eur J Endocrinol 150 (2004) 557-564
10. Spitzweg C., Scholz I.V., Bergert E.R., Tindall D.J., Young C.Y., Goke B., et al. Retinoic acid-induced stimulation of sodium iodide symporter expression and cytotoxicity of radioiodine in prostate cancer cells. Endocrinology 144 (2003) 3423-3432
11. - symporter expression in mammary glands. J Clin Endocrinol Metab 85 (2000) 2936-2943
12. Mandell R.B., Mandell L.Z., and Link Jr. C.J. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 59 (1999) 661-668
13. Gol Choe J., Kim Y.R., Kim K.N., Choo H.J., Shin J.H., Lee Y.J., et al. Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray. Nucl Med Commun 26 (2005) 1155-1162
14. - symporter gene. Endocrinology 138 (1997) 4493-4496
15. Gruning T., Tiepolt C., Zophel K., Bredow J., Kropp J., and Franke W.G. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise?. Eur J Endocrinol 148 (2003) 395-402
16. Altucci L., and Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 1 3 (2001) 181-193
17. Huang Y., Boskovic G., and Niles R.M. Retinoic acid-induced AP-1 transcriptional activity regulates B16 mouse melanoma growth inhibition and differentiation. J Cell Physiol 194 (2003) 162-170
18. Kogai T., Kanamoto Y., Che L.H., Taki K., Moatamed F., Schultz J.J., et al. Systemic retinoic acid treatment induces sodium/iodide symporter expression and radioiodide uptake in mouse breast cancer models. Cancer Res 64 (2004) 415-422
19. Schmutzler C., Schmitt T.L., Glaser F., Loos U., and Kohrle J. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cell Endocrinol 189 (2002) 145-155
20. Kogai T., Schultz J.J., Johnson L.S., Huang M., and Brent G.A. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A 97 (2000) 8519-8524
21. Hsiao L.L., Stears R.L., Hong R.L., and Gullans S.R. Prospective use of DNA microarrays for evaluating renal function and disease. Curr Opin Nephrol Hypertens 9 (2000) 253-258
22. Vawter M.P., Barrett T., Cheadle C., Sokolov B.P., Wood III W.H., Donovan D.M., et al. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55 (2001) 641-650
23. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids - a review. Exp Clin Endocrinol Diabetes 109 (2001) 41-44
24. Nishikori M., Maesako Y., Ueda C., Kurata M., Uchiyama T., and Ohno H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 101 (2003) 2789-2796 [electronic publication 2002 Nov 2727]
25. Nolan G.P., Fujita T., Bhatia K., Huppi C., Liou H.C., Scott M.L., et al. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol 13 (1993) 3557-3566
26. Watanabe N., Iwamura T., Shinoda T., and Fujita T. Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. EMBO J 16 (1997) 3609-3620
27. Barkett M., and Gilmore T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18 (1999) 6910-6924
28. Starenki D., Namba H., Saenko V., Ohtsuru A., and Yamashita S. Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 89 (2004) 410-418
29. Pacifico F., Mauro C., Barone C., Crescenzi E., Mellone S., Monaco M., et al. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem 279 (2004) 54610-54619 [electronic publication 52004 Oct 54618]
30. Erkel G., Anke T., and Sterner O. Inhibition of NF-kappa B activation by panepoxydone. Biochem Biophys Res Commun 226 (1996) 214-221
31. Shotwell J.B., Koh B., Choi H.W., Wood J.L., and Crews C.M. Inhibitors of NF-kappaB signaling: design and synthesis of a biotinylated isopanepoxydone affinity reagent. Bioorg Med Chem Lett 12 (2002) 3463-3466
32. Battista S., de Nigris F., Fedele M., Chiappetta G., Scala S., Vallone D., et al. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene 17 (1998) 377-385
33. Nagpal S., Athanikar J., and Chandraratna R.A. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem 270 (1995) 923-927
34. Salbert G., Fanjul A., Piedrafita F.J., Lu X.P., Kim S.J., Tran P., et al. Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta 1 promoter by antagonizing AP-1 activity. Mol Endocrinol 7 (1993) 1347-1356
35. Chuikin I.A., Lianguzova M.S., and Pospelov V.A. Transcription of c-fos gene and DNA binding activity of transcription factor AP-1 increase upon differentiation of mouse F9 teratocarcinoma cells. Tsitologiia 46 (2004) 1080-1090
36. Muller R., and Wagner E.F. Differentiation of F9 teratocarcinoma stem cells after transfer of c-fos proto-oncogenes. Nature 311 (1984) 438-442
37. de Groot R.P., and Kruijer W. Up-regulation of Jun/AP-1 during differentiation of N1E-115 neuroblastoma cells. Cell Growth Differ 2 (1991) 631-636
38. Kindregan H.C., Rosenbaum S.E., Ohno S., and Niles R.M. Characterization of conventional protein kinase C (PKC) isotype expression during F9 teratocarcinoma differentiation. Overexpression of PKC alpha alters the expression of some differentiation-dependent genes. J Biol Chem 269 (1994) 27756-27761
39. Lee J.H., and Kim K.T. Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells. J Neurochem 91 (2004) 634-647
40. Onose H., Emoto N., Sugihara H., Shimizu K., and Wakabayashi I. Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. Eur J Endocrinol 140 (1999) 169-173
41. Vasko V., Ferrand M., Di Cristofaro J., Carayon P., Henry J.F., and de Micco C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88 (2003) 2745-2752
42. Garcia-Rostan G., Zhao H., Camp R.L., Pollan M., Herrero A., Pardo J., et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21 (2003) 3226-3235
43. Eggo M.C., Hopkins J.M., Franklyn J.A., Johnson G.D., Sanders D.S., and Sheppard M.C. Expression of fibroblast growth factors in thyroid cancer. J Clin Endocrinol Metab 80 (1995) 1006-1011
44. Stolf B.S., Carvalho A.F., Martins W.K., Runza F.B., Brun M., Hirata Jr. R., et al. Differential expression of IGFBP-5 and two human ESTs in thyroid glands with goiter, adenoma and papillary or follicular carcinomas. Cancer Lett 191 (2003) 193-202
45. Aldred M.A., Huang Y., Liyanarachchi S., Pellegata N.S., Gimm O., Jhiang S., et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol 22 (2004) 3531-3539
46. Weber F., Shen L., Aldred M.A., Morrison C.D., Frilling A., Saji M., et al. Genetic classification of benign and malignant thyroid follicular neoplasia based on a 3-gene combination. J Clin Endocrinol Metab 15 (2005) 15